For the symptomatic relief of severe sore throats.
Merck Inc.,, known as MSD outside the United States and Canada, announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V 590 and V 591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK 4482 and MK 7110.
Zealand Pharma announced it has entered into an asset purchase agreement with MannKind Corporation ( to sell the V-Go insulin delivery device for $10 million and additional sales-based milestones).
Merck has announced that the Biologics License Application for V 503, its investigational 9-valent human papillomavirus (HPV) vaccine, has been...
Incyte announced positive topline results from its pivotal Phase III TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream, an investigational, nonsteroidal, anti-inflammatory, JAK inhibitor, topical therapy, in adolescent and adult patients (age greater than 12 years) with vitiligo.